Microsatellite instability and colorectal cancer prognosis

被引:297
作者
Benatti, P
Gafà, R
Barana, D
Marino, M
Scarselli, A
Pedroni, M
Maestri, I
Guerzoni, L
Roncucci, L
Menigatti, M
Roncari, B
Maffei, S
Rossi, G
Ponti, G
Santini, A
Losi, L
Di Gregorio, C
Oliani, C
de Leon, MP
Lanza, G
机构
[1] Univ Modena & Reggio Emilia, Dept Med & Med Specialties, I-41100 Modena, Italy
[2] Univ Modena & Reggio Emilia, Dept Pathol, I-41100 Modena, Italy
[3] Univ Ferrara, Dept Expt & Diagnost Med, I-44100 Ferrara, Italy
[4] St Anna Hosp, Div Clin Oncol, Ferrara, Italy
[5] Univ Verona, Dept Pathol, I-37100 Verona, Italy
[6] Civil Hosp Carpi, Pathol Unit, Carpi, Italy
[7] Ovest Vicentino, Complex Operat Unit Oncol, Vicenza, Italy
关键词
D O I
10.1158/1078-0432.CCR-05-1030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Many studies have evaluated the role of high levels of microsatellite instability (MSI) as a prognostic marker and predictor of the response to chemotherapy in colorectal cancer (CRC); however, the results are not conclusive. The aim of this study was to analyze the prognostic significance of high levels of MSI (MSI-H) in CRC patients in relation to fluorouracil-based chemotherapy. Experimental Design: In three different institutions, 1,263 patients with CRC were tested for the presence of MSI, and CRC-specific survival was then analyzed in relation to MSI status, chemotherapy, and other clinical and pathologic variables. Results:Two hundred and fifty-six tumors were MSI-H (20.3%): these were more frequently at a less advanced stage, right-sided, poorly differentiated, with mucinous phenotype, and expansive growth pattern than microsatellite stable carcinomas. Univariate and multivariale analyses of 5-year- specific survival revealed stage, tumor location, grade of differentiation, MSI, gender, and age as significant prognostic factors. The prognostic advantage of MSI tumors was particularly evident in stages II and III in which chemotherapy did not significantly affect the survival of MSI-H patients. Finally, we analyzed survival in MSI-H patients in relation to the presence of mismatch repair gene mutations. MSI-H patients with hereditary non - polyposis colorectal cancer showed a better prognosis as compared with sporadic MSI-H; however, in multivariate analysis, this difference disappeared. Conclusions:The type of genomic instability could influence the prognosis of CRC, in particular in stages II and Ill. Fluorouracil- based chemotherapy does not seem to improve survival among MSI-H patients.The survival benefit for patients with hereditary non - polyposis colorectal cancer is mainly determined by younger age and less advanced stage as compared with sporadic MSI-H counterpart.
引用
收藏
页码:8332 / 8340
页数:9
相关论文
共 38 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]   Colorectal cancer prevention and treatment [J].
Boland, CR ;
Sinicrope, FA ;
Brenner, DE ;
Carethers, JM .
GASTROENTEROLOGY, 2000, 118 (02) :S115-S128
[3]  
Boland CR, 1998, CANCER RES, V58, P5248
[4]  
Bubb VJ, 1996, ONCOGENE, V12, P2641
[5]   A founder MLH1 mutation in families from the districts of Modena and Reggio-Emilia in northern Italy with hereditary non-polyposis colorectal cancer associated with protein elongation and instability -: art. no. e34 [J].
Caluseriu, O ;
Di Gregorio, C ;
Lucci-Cordisco, E ;
Santarosa, M ;
Trojan, J ;
Brieger, A ;
Benatti, P ;
Pedroni, M ;
Colibazzi, T ;
Bellacosa, A ;
Neri, G ;
de Leon, MP ;
Viel, A ;
Genuardi, M .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (03) :e34
[6]   Mismatch repair proficiency and in vitro response to 5-fluorouracil [J].
Carethers, JM ;
Chauhan, DP ;
Fink, D ;
Nebel, S ;
Bresalier, RS ;
Howell, SB ;
Boland, CR .
GASTROENTEROLOGY, 1999, 117 (01) :123-131
[7]   Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer [J].
Carethers, JM ;
Smith, EJ ;
Behling, CA ;
Nguyen, L ;
Tajima, A ;
Doctolero, RT ;
Cabrera, BL ;
Goel, M ;
Arnold, CA ;
Miyai, K ;
Boland, CR .
GASTROENTEROLOGY, 2004, 126 (02) :394-401
[8]   The hereditary nonpolyposis colorectal cancer syndrome: Genetics and clinical implications [J].
Chung, DC ;
Rustgi, AK .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) :560-570
[9]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[10]   Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer [J].
de Leon, MP ;
Benatti, P ;
Di Gregorio, C ;
Pedroni, M ;
Losi, L ;
Genuardi, M ;
Viel, A ;
Fornasarig, M ;
Lucci-Cordisco, E ;
Anti, M ;
Ponti, G ;
Borghi, F ;
Lamberti, I ;
Roncucci, L .
BRITISH JOURNAL OF CANCER, 2004, 90 (04) :882-887